Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Rang in aandelen #4546
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aandeelprijs
$27.18
Laatst gesynchroniseerd: 2026-07-31
Marktkapitalisatie
$3.38B
Verandering (1 dag)
-1.41%
Verandering (1 jaar)
202.34%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)

Categorie

Healthcare
P/S-ratio voor Tango Therapeutics, Inc. (TNGX)
P/S-ratio op October 2026 TTM: 67.14
Volgens de meest recente financiële rapporten en aandelenkoers van Tango Therapeutics, Inc. is de huidige P/S-ratio (TTM) 67.14. Eind 2023 had het bedrijf een P/S-ratio van 25.63.
P/S-ratiohistoriek voor Tango Therapeutics, Inc. van 2019 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 67.14 737.15%
2024 8.02 -68.70%
2023 25.63 0.08%
2022 25.61 39.62%
2021 18.34 -61.56%
2020 47.71 1,179.46%
2019 3.73 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
10.02 -85.07%
US
40.55 -39.60%
US
3.96 -94.10%
AU
- -
CH
10.15 -84.89%
NL